Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

已完结 10 由 YYYY 发布于 2025/9/16 16:08:47

DOI:10.1016/S0140-6736(23)01200-X
作者：W Timothy Garvey,?Juan P Frias,?Ania M Jastreboff,?Carel W le Roux,?Naveed Sattar,?Diego Aizenberg,?Huzhang Mao,?Shuyu Zhang,?Nadia N Ahmad,?Mathijs C Bunck,?Imane Benabbad,?Xiaotian M Zhang
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent in

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Pre-Fluorination Interface Engineering of Silicon-Based Anode for Durable Lithium-Ion Batteries.